A share price of Vera Therapeutics Inc [VERA] is currently trading at $25.59, down -2.85%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VERA shares have gain 7.66% over the last week, with a monthly amount glided 15.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vera Therapeutics Inc [NASDAQ: VERA] stock has seen the most recent analyst activity on August 04, 2025, when Wolfe Research downgraded its rating to a Peer Perform. On February 04, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $49 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $58 on January 28, 2025. Wells Fargo initiated its recommendation with a Overweight and recommended $70 as its price target on November 21, 2024. In a note dated January 25, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $26 on this stock.
Vera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $18.53 and $51.61. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $25.59 at the most recent close of the market. An investor can expect a potential return of 154.01% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.47 and Total Capital is -0.43. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vera Therapeutics Inc [NASDAQ:VERA] is 16.92. As well, the Quick Ratio is 16.92, while the Cash Ratio is 1.46.
Transactions by insiders
Recent insider trading involved ENRIGHT PATRICK G, Director, that happened on Jun 23 ’25 when 0.21 million shares were purchased. Director, ENRIGHT PATRICK G completed a deal on Jun 24 ’25 to buy 40607.0 shares. Meanwhile, PRESIDENT AND CEO Fordyce Marshall sold 10613.0 shares on Feb 21 ’25.
